Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual ...
Source: Nature
Published:
<p>SWI/SNF-deficient cancers characterized by dual SMARCA4/SMARCA2 loss, including subsets of lung adenocarcinoma and small cell carcinoma of the ovary, hypercalcemic type, represent a major therapeutic challenge. While SMARCA2 paralog-targeting strategies exist for single-subunit loss of SMARCA4, d